The focus on PDE4B and PDE6H in relation to ocular diseases has intensified, with research indicating PDE4B’s dysregulation in conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD), positing it as a promising therapeutic target. Here, PDE6H is linked to glaucoma.